Interpace Diagnostics Group Reports Fourth Quarter and Full Year 2016 Financial Results, Business Progress Against Plan and Recent Accomplishments

Thursday, March 30, 2017 Research News
Email Print This Page Comment
Font : A-A+

Revenue Grew 39%, to $13.1 Million in 2016

Reconciliation of Adjusted EBITDA (Unaudited)

($ in thousands)

Quarters Ended

Years Ended

December 31,

December 31,

2016

2015

2016

2015

Income (loss) from continuing operations

$        6,304

$    (19,259)

$   (8,410)

$ (31,070)

Depreciation and amortization- continuing operations

992

1,136

4,292

4,470

Stock-based compensation - continuing operations

23

2,138

131

3,128

Taxes

(108)

#

(449)

(162)

#

(13,136)

Interest expense

544

898

2,144

3,705

Asset impairment

-

-

3,363

-

Loss on extinguishment of debt

-

1,873

-

1,873

Goodwill impairment

-

15,666

-

15,666

Change in fair value of contingent consideration

(10,686)

(7,993)

(11,860)

(7,993)

Adjusted EBITDA

$       (2,931)

$       (5,990)

$ (10,502)

$ (23,357)



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook